NeuroPace, Inc.
HealthcareNASDAQ:NPCE · NASDAQ Global Market
-$0.20 today
Vol 0.08M · Avg 0.19M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$99.5M of revenue converted into -$21.6M of net income for the selected period. Gross margin is 78.4% and net margin is -22.5%, showing how much revenue survives after costs and taxes. EPS is $-0.65, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $100.0M +25.1% | $79.9M +22.1% | $65.4M +43.7% | $45.5M +0.7% | $45.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $22.8M +9.3% | $20.8M +20.4% | $17.3M +32.8% | $13.0M +10.9% | $11.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $77.2M +30.7% | $59.1M +22.8% | $48.1M +48.1% | $32.5M -2.8% | $33.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 77.2% +3.3pp | 73.9% +0.4pp | 73.6% +2.2pp | 71.4% -2.6pp | 74.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $27.9M +17.9% | $23.7M +13.8% | $20.8M -5.3% | $21.9M +20.5% | $18.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $65.7M +15.0% | $57.1M +4.7% | $54.5M +6.2% | $51.3M +31.8% | $39.0M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $93.6M +15.9% | $80.8M +7.3% | $75.3M +2.7% | $73.3M +28.2% | $57.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.9M +10.1% | $1.8M +10.2% | $1.6M -46.3% | $3.0M +909.1% | $296.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$12.1M +27.2% | -$16.6M +27.4% | -$22.8M +37.6% | -$36.6M -28.9% | -$28.4M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -12.1% +8.7pp | -20.7% +14.2pp | -34.9% +45.4pp | -80.3% -17.5pp | -62.8% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$16.3M +24.6% | -$21.7M +20.3% | -$27.2M +33.4% | -$40.8M -71.9% | -$23.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -16.3% +10.8pp | -27.1% +14.4pp | -41.5% +48.1pp | -89.6% -37.1pp | -52.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.8M -6.9% | $3.0M -0.9% | $3.0M +93.3% | $1.6M +252.2% | $448.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $7.5M -15.2% | $8.8M +3.3% | $8.5M +13.1% | $7.5M +1.6% | $7.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$5.1M +6.3% | -$5.5M +5.4% | -$5.8M +8.0% | -$6.3M +49.1% | -$12.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$21.5M +20.9% | -$27.1M +17.6% | -$33.0M +30.0% | -$47.1M -30.5% | -$36.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -21.5% +12.5pp | -34.0% +16.4pp | -50.4% +53.1pp | -103.4% -23.6pp | -79.9% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$21.5M +20.9% | -$27.1M +17.6% | -$33.0M +30.0% | -$47.1M -30.5% | -$36.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -21.5% +12.5pp | -34.0% +16.4pp | -50.4% +53.1pp | -103.4% -23.6pp | -79.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +29.0% | -$1 +26.8% | -$1 +33.5% | -$2 +12.0% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +29.0% | -$1 +26.8% | -$1 +33.5% | -$2 +12.0% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $32.7M +12.3% | $29.1M +12.7% | $25.9M +5.1% | $24.6M +48.1% | $16.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $32.7M +12.3% | $29.1M +12.7% | $25.9M +5.1% | $24.6M +48.1% | $16.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
BrainsWay Ltd.
NASDAQ:BWAY
$573.83M
Cerus Corporation
NASDAQ:CERS
$512.94M
Delcath Systems, Inc.
NASDAQ:DCTH
$404.59M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
RxSight, Inc.
NASDAQ:RXST
$194.98M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
Genelux Corporation
NASDAQ:GNLX
$111.35M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$106.17M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NPCE generate?
NeuroPace, Inc. (NPCE) reported $99.99M of revenue in fiscal 2025.
Is NPCE profitable?
NeuroPace, Inc. (NPCE) reported -$21,465,000.00 of net income, with a net margin of -21.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.